ClinicalTrials.gg
TerminatedNCT06032546Updated Nov 6, 2026Results posted

A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion or Subcutaneous (SC) Injection of Budigalimab and/or ABBV-382

A Phase 2 interventional study of Budigalimab and Placebo for Budigalimab in Human Immuno-deficiency Virus (HIV) Disease, sponsored by AbbVie. Terminated at 80 sites in 13 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-06.

Primary conditionnone(registry's first term: Disease)No conditionIs this wrong?Disease describes something many studies share rather than a condition a study is about. The study names no condition we can place it under, so it is not compared with other studies by condition.

Sponsored by AbbVie · Phase 2, Interventional, and Treatment

Why this study was terminated
Company Decision
Updated Nov 6, 2026Results postedStudy documents posted+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
163
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

Human immuno-deficiency virus (HIV) is the virus that causes Acquired Immuno-Deficiency Syndrome (AIDS). HIV disease is considered to be a chronic disease requiring lifelong therapy. The purpose of this study is to assess change in disease activity, adverse events, tolerability, and how the drug moves through the body.

Budigalimab and ABBV-382 are investigational drugs being developed for the treatment of HIV disease. In Part 1, participants are placed in 1 of 5 groups, called treatment arms. Each group receives a different treatment. There is a 1 in 7 chance that participants will be assigned to placebo (A placebo is not a drug and it is not expected to have any chemical effects on your body and it is not designed to treat any disease or illness). In Part 2, eligible participants will be placed in an open-label arm to receive Budigalimab. Approximately 160 adult participants living with HIV disease on stable antiretroviral therapy (ART) willing to undergo Analytical Treatment Interruption (ATI) will be enrolled at approximately 90 sites worldwide.

In Part 1, participants will receive 4 doses of intravenous (IV) budigalimab or placebo combined with 3 doses of IV ABBV-382 or placebo for an 8 week dosing period. In Part 2, participants will receive 4 doses of open-label subcutaneous (SC) Budigalimab for a 6 week dosing period. Participants need to be stable on antiretroviral therapy to participate in the study. If participant qualifies to the study, on the day they receive the first injection, participants will be asked to stop antiretroviral medications (also referred to as analytical treatment interruption or ATI) for 112 weeks or until meeting specific criteria to restart antiretroviral medications. Participants will undergo a closely monitored ART interruption. Protocol-defined ART restart criteria includes participant's request. Participants will be followed for up to approximately 112 weeks.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. There will be an option for virtual or home health visits for some of the follow-up visits. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

02

Conditions studied

  • Human Immuno-deficiency Virus (HIV) Disease

Browse trials for

Keywords

  • Human immuno-deficiency virus (HIV) Disease
  • Budigalimab
  • ABBV-382
03

In context

Lead sponsor

AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.

Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A condition of general good health in the opinion of the investigator, based upon the results of a medical history, physical examination, vital signs, laboratory profile, and a 12-lead (ECG).
  • Must be on antiretroviral therapy (ART) for at least 12 months prior to screening and on a stable ART regimen for at least 8 weeks prior to screening (current ART regimen cannot include an Non-nucleoside reverse transcriptase inhibitor [NNRTI] or long-acting ART).
  • Negative human immuno-deficiency virus ()-2 antibody (Ab)
  • Cluster of differentiation 4 (CD4+) T cell count >= 500 cells/μL at screening and no known evidence of \< 500 cells/μL in the last 12 months prior to screening
  • Participant must have plasma HIV-1 ribonucleic acid (RNA) below the lower limit of quantitation (LLOQ) at screening and for at least 12 months prior to screening

Exclusion criteria

Exclusion Criteria:

  • Prior exposure to long acting antiretrovirals within 24 weeks or within a period defined by 5 half-lives, whichever is longer, prior to randomization and prior to the first dose of study drug.
  • History of CD4+ T cell nadir of \<= 200 cells/μL during chronic infection.
  • History of medical disorders (other than HIV-1 infection) that, in the opinion of the investigator, might expose the participant to undue risk of harm, confound study outcomes or prevent the participant from completing the study.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
163 participants (actual)

Study arms

  • Placebo comparator
    Arm A: Placebo

    Participants will receive budigalimab placebo on Day 1, and Weeks 2, 4, and 6 in combination with ABBV-382 matching placebo on Day 1 and Weeks 4 and 8.

    Drug: Placebo for Budigalimab · Drug: Placebo for ABBV-382

  • Experimental
    Arm B: Budigalimab Dose A

    Participants will receive budigalimab Dose A on Day 1 and Weeks 2, 4, and 6 in combination with ABBV-382 matching placebo Day 1 and Weeks 4 and 8.

    Drug: Budigalimab · Drug: Placebo for ABBV-382

  • Experimental
    Arm C: ABBV-382 Dose A

    Participants will receive budigalimab placebo on Day 1 and Weeks 2, 4, and 6 in combination with ABBV-382 Dose A on Day 1 and Weeks 4 and 8.

    Drug: Placebo for Budigalimab · Drug: ABBV-382

  • Experimental
    Arm D: Budigalimab Dose A + ABBV-382 Dose B

    Participants will receive budigalimab Dose A on Day 1 and Weeks 2, 4, and 6 in combination with ABBV-382 Dose B on Day 1 and Weeks 4 and 8.

    Drug: Budigalimab · Drug: ABBV-382

  • Experimental
    Arm E: Budigalimab Dose A + ABBV-382 Dose A

    Participants will receive budigalimab Dose A on Day 1 and Weeks 2, 4, and 6 in combination with ABBV-382 Dose A on Day 1 and Weeks 4 and 8.

    Drug: Budigalimab · Drug: ABBV-382

  • Experimental
    Arm F: Budigalimab Dose B

    Participants will receive open-label budigalimab Dose B on Day 1 and Weeks 2, 4, and 6 (Note, no ABBV-382 or placebo will be administered).

    Drug: Budigalimab

Interventions

  • Intravenous (IV) Infusion

    Also known as: ABBV-181

  • DrugPlacebo for Budigalimab

    IV Infusion

  • IV Infusion

  • DrugPlacebo for ABBV-382

    IV Infusion

  • Subcutaneous (SC) Injection

    Also known as: ABBV-181

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Viral Control Without Antiretroviral Therapy (ART) Restart

    Percentage of participants who achieve viral control (viral load \< 1000 copies/mL) without ART restart at Week 24.

    Time frame: Week 24

  2. Number of Participants With Adverse Events (AEs)

    An AE is defined as any untoward medical occurrence in a patient or clinical investigation in which a participant is administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.

    Time frame: Up to approximately Week 112

Secondary outcomes

  1. Median Peak Log10 Viral Load (At Rebound) Prior to Re-Starting ART

    The median peak log10 viral load (at rebound) before re-starting ART.

    Time frame: Up to 112 weeks

  2. Median Time to First Rebound to ≥ 1000 Copies/mL During ART Interruption

    The median time to first rebound to ≥ 1000 copies/mL during ART interruption.

    Time frame: Up to 112 weeks

07

Results

Posted Nov 6, 2026

Participant flow

Participant flow — Overall Study
MilestonePart 1: PlaceboPart 1: Budigalimab IV MonoPart 1: ABBV-382 IV MonoPart 1: ABBV-1882 IV LowPart 1: ABBV-1882 IV HighPart 2: Budigalimab SC Mono
Started202020424021
Received randomized study treatment202019424021
Received study treatment other than randomized001000
Completed study treatment71111161615
Completed011120
Not completed201919413821
Withdrew: Lost to follow-up100000
Withdrew: Withdrawal by subject301721
Withdrew: Withdrawal by subject due to adverse events010000
Withdrew: Study terminated by sponsor161718343620
Withdrew: Not disclosed010000

Outcome measures

PrimaryPercentage of Participants With Viral Control Without Antiretroviral Therapy (ART) Restart

Percentage of participants who achieve viral control (viral load \< 1000 copies/mL) without ART restart at Week 24.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With Viral Control Without Antiretroviral Therapy (ART) Restart
percentage of participantsPart 1: PlaceboPart 1: Budigalimab IV MonoPart 1: ABBV-382 IV MonoPart 1: ABBV-1882 IV LowPart 1: ABBV-1882 IV HighPart 2: Budigalimab SC Mono
Percentage of Participants With Viral Control Without Antiretroviral Therapy (ART) Restart5.0 (0.26 to 21.61)10.0 (1.81 to 28.26)0 (0.00 to 13.91)23.8 (13.53 to 37.03)10.0 (3.49 to 21.44)4.8 (0.24 to 20.67)
Statistical analysis
  • Part 1: Placebo vs Part 1: Budigalimab IV Mono · Mantel-Haenszel · p = 0.5533 · Response rate difference: 5.0 · 90% CI -8.64 to 18.64
  • Part 1: Placebo vs Part 1: ABBV-382 IV Mono · Mantel-Haenszel · p = 0.3173 · Response rate difference: -5.0 · 90% CI -13.02 to 3.02
  • Part 1: Placebo vs Part 1: ABBV-1882 IV Low · Mantel-Haenszel · p = 0.0722 · Response rate difference: 18.8 · 90% CI 5.35 to 32.27
  • Part 1: Placebo vs Part 1: ABBV-1882 IV High · Mantel-Haenszel · p = 0.5124 · Response rate difference: 5.0 · 90% CI -6.19 to 16.19
PrimaryNumber of Participants With Adverse Events (AEs)

An AE is defined as any untoward medical occurrence in a patient or clinical investigation in which a participant is administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.

Time frame:
Up to approximately Week 112
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs)
ParticipantsPart 1: PlaceboPart 1: Budigalimab IV MonoPart 1: ABBV-382 IV MonoPart 1: ABBV-1882 IV LowPart 1: ABBV-1882 IV HighPart 2: Budigalimab SC Mono
Number of Participants With Adverse Events (AEs)171915403617
SecondaryMedian Peak Log10 Viral Load (At Rebound) Prior to Re-Starting ART

The median peak log10 viral load (at rebound) before re-starting ART.

Time frame:
Up to 112 weeks
Reported as:
Median · log10 (copies/mL)
Median Peak Log10 Viral Load (At Rebound) Prior to Re-Starting ART
log10 (copies/mL)Part 1: PlaceboPart 1: Budigalimab IV MonoPart 1: ABBV-382 IV MonoPart 1: ABBV-1882 IV LowPart 1: ABBV-1882 IV HighPart 2: Budigalimab SC Mono
Median Peak Log10 Viral Load (At Rebound) Prior to Re-Starting ART5.35 (1.3 to 6.6)5.01 (2.3 to 7.3)5.44 (3.7 to 7.7)5.22 (1.0 to 6.8)5.35 (1.5 to 6.6)4.96 (3.7 to 7.3)
Statistical analysis
  • Part 1: Placebo vs Part 1: Budigalimab IV Mono · Wilcoxon (Mann-Whitney) · p = 0.2211 · Median difference (final values): -0.3 · 90% CI -0.86 to 0.17Using Hodges-Lehmann estimation
  • Part 1: Placebo vs Part 1: ABBV-382 IV Mono · Wilcoxon (Mann-Whitney) · p = 0.9888 · Median difference (final values): 0.1 · 90% CI -0.41 to 0.52Using Hodges-Lehmann estimation
  • Part 1: Placebo vs Part 1: ABBV-1882 IV Low · Wilcoxon (Mann-Whitney) · p = 0.4710 · Median difference (final values): -0.1 · 90% CI -0.79 to 0.25Using Hodges-Lehmann estimation
  • Part 1: Placebo vs Part 1: ABBV-1882 IV High · Wilcoxon (Mann-Whitney) · p = 0.7051 · Median difference (final values): 0.0 · 90% CI -0.55 to 0.35Using Hodges-Lehmann estimation
SecondaryMedian Time to First Rebound to ≥ 1000 Copies/mL During ART Interruption

The median time to first rebound to ≥ 1000 copies/mL during ART interruption.

Time frame:
Up to 112 weeks
Reported as:
Median · days
Median Time to First Rebound to ≥ 1000 Copies/mL During ART Interruption
daysPart 1: PlaceboPart 1: Budigalimab IV MonoPart 1: ABBV-382 IV MonoPart 1: ABBV-1882 IV LowPart 1: ABBV-1882 IV HighPart 2: Budigalimab SC Mono
Median Time to First Rebound to ≥ 1000 Copies/mL During ART Interruption26 (23.0 to 30.0)30 (22.0 to 43.0)30 (23.0 to 37.0)24 (22.0 to 30.0)26 (23.0 to 30.0)30 (23.0 to 32.0)

Adverse events

Collected over All-cause mortality and adverse event tables include AEs reported from the time of informed consent and treatment-emergent events reported from the time of study drug administration to the end of the study. The median time on follow-up was 469, 427.5, 421, 389.5, 442 days for participants receiving Placebo, Budigalimab IV Mono, ABBV-382 IV Mono, ABBV-1882 IV Low, ABBV-1882 IV High in Part 1, and 253 days for participants receiving Budigalimab SC Mono in Part 2, respectively.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1: Placebo0/21 (0%)0/21 (0%)13/21 (61.9%)
Part 1: Budigalimab IV Mono0/20 (0%)5/20 (25%)18/20 (90%)
Part 1: ABBV-382 IV Mono0/19 (0%)1/19 (5.3%)15/19 (78.9%)
Part 1: ABBV-1882 IV Low0/42 (0%)8/42 (19%)35/42 (83.3%)
Part 1: ABBV-1882 IV High0/40 (0%)8/40 (20%)34/40 (85%)
Part 2: Budigalimab SC Mono0/21 (0%)0/21 (0%)12/21 (57.1%)
Most frequent serious events
Showing 10 of 20
Most frequent serious events
EventPart 1: PlaceboPart 1: Budigalimab IV MonoPart 1: ABBV-382 IV MonoPart 1: ABBV-1882 IV LowPart 1: ABBV-1882 IV HighPart 2: Budigalimab SC Mono
APPENDICITISInfections and infestations0/212/200/190/421/400/21
PYELONEPHRITIS ACUTEInfections and infestations0/210/201/190/420/400/21
HERNIA PAINGeneral disorders0/211/200/190/420/400/21
CELLULITISInfections and infestations0/211/200/190/420/400/21
GLIOBLASTOMANeoplasms benign, malignant and unspecified (incl cysts and polyps)0/211/200/190/420/400/21
RETROVIRAL REBOUND SYNDROMEInfections and infestations0/210/200/192/420/400/21
MYOCARDIAL INFARCTIONCardiac disorders0/210/200/190/421/400/21
OBSTRUCTIVE PANCREATITISGastrointestinal disorders0/210/200/190/421/400/21
HYPERSENSITIVITYImmune system disorders0/210/200/190/421/400/21
ABSCESSInfections and infestations0/210/200/190/421/400/21
Most frequent other events
Showing 10 of 111
Most frequent other events
EventPart 1: PlaceboPart 1: Budigalimab IV MonoPart 1: ABBV-382 IV MonoPart 1: ABBV-1882 IV LowPart 1: ABBV-1882 IV HighPart 2: Budigalimab SC Mono
FATIGUEGeneral disorders5/215/204/199/428/403/21
RETROVIRAL REBOUND SYNDROMEInfections and infestations1/213/203/193/424/405/21
MYALGIAMusculoskeletal and connective tissue disorders2/211/204/191/423/401/21
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations1/214/201/196/423/402/21
HEADACHENervous system disorders3/212/203/196/425/403/21
ABDOMINAL PAIN UPPERGastrointestinal disorders0/210/200/190/426/400/21
DIARRHOEAGastrointestinal disorders3/212/200/195/426/401/21
COVID-19Infections and infestations1/213/201/193/422/401/21
NAUSEAGastrointestinal disorders2/210/201/196/422/402/21
NASOPHARYNGITISInfections and infestations0/211/202/191/425/401/21

Baseline characteristics

ITT Population

Age, Continuous
Age, Continuous(years)Part 1: PlaceboPart 1: Budigalimab IV MonoPart 1: ABBV-382 IV MonoPart 1: ABBV-1882 IV LowPart 1: ABBV-1882 IV HighPart 2: Budigalimab SC MonoTotal
Mean49.1 ± 12.4547.3 ± 13.4444.0 ± 10.7544.6 ± 13.5849.3 ± 10.7242.1 ± 11.9246.2 ± 12.32
Age, Customized
Age, Customized(Participants)Part 1: PlaceboPart 1: Budigalimab IV MonoPart 1: ABBV-382 IV MonoPart 1: ABBV-1882 IV LowPart 1: ABBV-1882 IV HighPart 2: Budigalimab SC MonoTotal
< 40 years7591781056
40 - 64 years11141022281196
≥ 65 years21134011
Sex/Gender, Customized
Sex/Gender, Customized(Participants)Part 1: PlaceboPart 1: Budigalimab IV MonoPart 1: ABBV-382 IV MonoPart 1: ABBV-1882 IV LowPart 1: ABBV-1882 IV HighPart 2: Budigalimab SC MonoTotal
Gender Identity — Cisgender191818403721153
Gender Identity — Transgender Male0000000
Gender Identity — Transgender Female1000102
Gender Identity — Gender Fluid0121206
Gender Identity — Other0000000
Gender Identity — Missing0101002
Sex: Female, Male
Sex: Female, Male(Participants)Part 1: PlaceboPart 1: Budigalimab IV MonoPart 1: ABBV-382 IV MonoPart 1: ABBV-1882 IV LowPart 1: ABBV-1882 IV HighPart 2: Budigalimab SC MonoTotal
Female42185121
Male161819343520142
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part 1: PlaceboPart 1: Budigalimab IV MonoPart 1: ABBV-382 IV MonoPart 1: ABBV-1882 IV LowPart 1: ABBV-1882 IV HighPart 2: Budigalimab SC MonoTotal
Hispanic or Latino7991211553
Not Hispanic or Latino131111302916110
Unknown or Not Reported0000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part 1: PlaceboPart 1: Budigalimab IV MonoPart 1: ABBV-382 IV MonoPart 1: ABBV-1882 IV LowPart 1: ABBV-1882 IV HighPart 2: Budigalimab SC MonoTotal
American Indian or Alaska Native0100001
Asian1112207
Native Hawaiian or Other Pacific Islander1000001
Black or African American42687936
White141613312912115
More than one race0001203
Unknown or Not Reported0000000
08

Study locations

80 sites
  • University of Alabama at Birmingham, 1917 Research Clinic /ID# 257549
    Birmingham, Alabama 35222-2309, United States
  • Franco Felizarta, Md /Id# 256927
    Bakersfield, California 93301, United States
  • AHF Research Center /ID# 257025
    Beverly Hills, California 90211, United States
  • Long Beach Education and Research Consultants /ID# 257552
    Long Beach, California 90813-3267, United States
  • AHF Healthcare Center- Hollywood /ID# 257026
    Los Angeles, California 90027, United States
  • Los Angeles LGBT Center /ID# 258407
    Los Angeles, California 90028-6213, United States
  • Ruane Clinical Research Group /ID# 256932
    Los Angeles, California 90036, United States
  • Palmtree Clinical Research Inc. /Id# 258409
    Palm Springs, California 92262, United States
  • Optimus Medical /ID# 257182
    San Francisco, California 94102, United States
  • Quest Clinical Research /ID# 256928
    San Francisco, California 94115-3037, United States
  • Washington Health Institute /ID# 259336
    Washington D.C., District of Columbia 20017, United States
  • Midland Florida Clinical Research Center /ID# 257101
    DeLand, Florida 32720-0920, United States
  • Ahf Healthcare Center - Northpoint /ID# 256934
    Fort Lauderdale, Florida 33308, United States
  • Midway Immunology and Research Center /ID# 256930
    Ft. Pierce, Florida 34982, United States
  • Advanced Pharma CR, LLC /ID# 259335
    Miami, Florida 33147, United States
  • Orlando Immunology Center /ID# 256931
    Orlando, Florida 32803, United States
  • Bliss Health /ID# 257827
    Orlando, Florida 32806-3300, United States
  • Baycare Medical Group - Tampa /ID# 256953
    Tampa, Florida 33614, United States
  • The Pierone Research Institute /ID# 257022
    Vero Beach, Florida 32960-6541, United States
  • Triple O Research Institute /ID# 256929
    West Palm Beach, Florida 33407, United States
  • Winship At Emory University Hospital Midtown /ID# 258410
    Atlanta, Georgia 30308, United States
  • Metro Infectious Disease Consultants /ID# 256955
    Decatur, Georgia 30033, United States
  • Howard Brown Health Center /ID# 257485
    Chicago, Illinois 60613-2010, United States
  • Claudia T. Martorell MD LLC dba The Research Institute /ID# 259155
    Springfield, Massachusetts 01105-1406, United States
  • KC CARE Health Center - Midtown South /ID# 257178
    Kansas City, Missouri 64111, United States
  • Las Vegas Research Center /ID# 257619
    Las Vegas, Nevada 89106, United States
  • Cooper University Health Care - Camden /ID# 258133
    Camden, New Jersey 08103, United States
  • Saint Michael's Medical Center /ID# 258802
    Newark, New Jersey 07102, United States
  • South Jersey Infectious Disease /ID# 257840
    Somers Point, New Jersey 08244, United States
  • The University of New Mexico /ID# 257533
    Albuquerque, New Mexico 87106, United States
  • Suny Upstate University Hospital Community Campus /ID# 257847
    Syracuse, New York 13215, United States
  • Jacobi Medical Center /ID# 257849
    The Bronx, New York 10461, United States
  • Montefiore Medical Center /ID# 257792
    The Bronx, New York 10467, United States
  • East Carolina University - Brody School of Medicine /ID# 257544
    Greenville, North Carolina 27834, United States
  • Atrium Health Wake Forest Baptist Medical Center /ID# 257542
    Winston-Salem, North Carolina 27157, United States
  • Central Texas Clinical Research /ID# 256920
    Austin, Texas 78705-3326, United States
  • Prism Health North Texas - Oak Cliff Health Center /ID# 256933
    Dallas, Texas 75208-4599, United States
  • North Texas Infectious Diseases Consultants, P.A /ID# 257592
    Dallas, Texas 75246, United States
  • University of Texas Southwestern Medical Center /ID# 257551
    Dallas, Texas 75390-7208, United States
  • Texas Center for Infectious Disease Associates /ID# 257183
    Fort Worth, Texas 76104, United States
  • The Crofoot Research Center, Inc /ID# 256921
    Houston, Texas 77098-3900, United States
  • DCOL Center for Clinical Research /ID# 257093
    Longview, Texas 75605, United States
  • Wisconsin Medical Center /ID# 257498
    Milwaukee, Wisconsin 53226, United States
  • Universite Libre de Bruxelles - Hopital Erasme /ID# 257433
    Anderlecht, Brussels Capital 1070, Belgium
  • CHU Saint Pierre /ID# 257447
    Brussels, Brussels Capital 1000, Belgium
  • Cliniques Universitaires UCL Saint-Luc /ID# 257444
    Brussels, Brussels Capital 1200, Belgium
  • UZ Gent /ID# 257446
    Ghent, Oost-Vlaanderen 9000, Belgium
  • Ricardo Diaz Scientific Solution /ID# 257335
    São Paulo, São Paulo 04037-030, Brazil
  • Spectrum Health Vancouver /ID# 260791
    Vancouver, British Columbia V6Z 2T1, Canada
  • Ottawa Hospital Research Institute /ID# 256993
    Ottawa, Ontario K1H 8L6, Canada
  • Duplicate_Toronto General Hospital /ID# 256994
    Toronto, Ontario M5G 2C4, Canada
  • McGill University Health Centre - Glen Site. /ID# 256992
    Montreal, Quebec H4A 3J1, Canada
  • CHU de Quebec-Université Laval hôpital CHUL /ID# 261611
    Québec, Quebec G1V 4G2, Canada
  • Regina General Hospital - Infectious Disease Clinic /ID# 260243
    Regina, Saskatchewan S4P 0W5, Canada
  • AP-HP - Hopital Saint-Antoine /ID# 258090
    Paris, 75012, France
  • AP-HP - Hopital Tenon /ID# 258091
    Paris, 75020, France
  • Infektiologikum /ID# 257112
    Frankfurt am Main, Hesse 60596, Germany
  • Universitaetsklinikum Bonn /ID# 257113
    Bonn, North Rhine-Westphalia 53127, Germany
  • zibp-Zentrum fuer Infektiologie /ID# 257110
    Berlin, 10439, Germany
  • IRCCS Ospedale San Raffaele /ID# 259820
    Milan, Milano 20132, Italy
  • ASST Grande Ospedale Metropolitano Niguarda /ID# 257410
    Milan, Milano 20162, Italy
  • Azienda Ospedaliera Universitaria Federico II - Naples /ID# 257412
    Naples, Napoli 80131, Italy
  • Azienda Ospedaliero-Universitaria di Modena /ID# 257411
    Modena, 41124, Italy
  • NHO Nagoya Medical Center /ID# 261433
    Nagoya, Aichi-ken 460-0001, Japan
  • National Hospital Organization Osaka National Hospital /ID# 261520
    Osaka, Osaka 540-0006, Japan
  • IMSUT Hospital, The Institute of Medical Science, The University of Tokyo /ID# 265344
    Tokyo, 108-8639, Japan
  • Wojewodzki Szpital Obserwacyjno-Zakazny im. Tadeusza Browicza /ID# 259184
    Bydgoszcz, Kuyavian-Pomeranian Voivodeship 85-030, Poland
  • Punkt Zdrowia /ID# 257950
    Gdansk, Pomeranian Voivodeship 80-405, Poland
  • Clinical Research Puerto Rico /ID# 256956
    San Juan, 00909-1711, Puerto Rico
  • HOPE Clinical Research /ID# 257487
    San Juan, 00909, Puerto Rico
  • Wits RHI Research Centre /ID# 257354
    Johannesburg, Gauteng 2001, South Africa
  • Perinatal HIV Research Unit (PHRU) /ID# 257350
    Johannesburg, Gauteng 2013, South Africa
  • Clinical HIV Research Unit (CHRU) /ID# 257358
    Johannesburg, Gauteng 2092, South Africa
  • Ezintsha Research Centre /ID# 257391
    Johannesburg, Gauteng 2193, South Africa
  • Hospital Universitario Germans Trias i Pujol /ID# 257268
    Badalona, Barcelona 08916, Spain
  • Hospital Clinic de Barcelona /ID# 257269
    Barcelona, 08036, Spain
  • Hospital Universitario Ramon y Cajal /ID# 257266
    Madrid, 28034, Spain
  • Hospital Universitario La Paz /ID# 257170
    Madrid, 28046, Spain
  • Royal Free Hospital /ID# 257453
    London, Greater London NW3 2QG, United Kingdom
  • Dup_Guys and St Thomas NHS Foundation Trust - Guy's Hospital /ID# 257761
    London, Greater London SE1 9RT, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.

Supporting information: Study protocol, Statistical analysis plan

Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/

Access criteria: To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2023 to primary completion in Sep 2025, 23 months.

Results were first posted in Nov 2026, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 5, 2023
First posted
Sep 13, 2023
StartActual
Oct 12, 2023
Primary completionActual
Sep 22, 2025
CompletionActual
Sep 22, 2025
Results first posted
Nov 6, 2026
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 6, 2026
Sites
6 sites added, 6 sites removed
Show 6 added (3 United States, 2 Canada, 1 Italy)
  • Ahf Healthcare Center - Northpoint /ID# 256934 · Fort Lauderdale, United States
  • Metro Infectious Disease Consultants /ID# 256955 · Decatur, United States
  • The University of New Mexico /ID# 257533 · Albuquerque, United States
  • Duplicate_Toronto General Hospital /ID# 256994 · Toronto, Canada
  • McGill University Health Centre - Glen Site. /ID# 256992 · Montreal, Canada
  • Azienda Ospedaliera Universitaria Federico II - Naples /ID# 257412 · Naples, Italy
Show 6 removed
  • AIDS Healthcare Foundation (AHF) - Healthcare Center - Northpoint /ID# 256934 · Fort Lauderdale, United States
  • Metro Infectious Disease Consultants, P.L.L.C /ID# 256955 · Decatur, United States
  • Unmhsc /Id# 257533 · Albuquerque, United States
  • Toronto General Hospital /ID# 256994 · Toronto, Canada
  • McGill University Health Centre - Glen Site /ID# 256992 · Montreal, Canada
  • Azienda Ospedaliera Universitaria Federico II /ID# 257412 · Naples, Italy
Nov 6, 2026
Primary outcomes
2 edited
What changed in the outcomes
  • EditedPercentage of Participants withWith Viral Control Without Antiretroviral Therapy (ART) RestartTime frame: Week 24
  • EditedNumber of Participants withWith Adverse Events (AEs)Time frame: Up to approximately Week 112
Nov 6, 2026
Documents
Secondary outcomes
2 edited
What changed in the outcomes
  • EditedMedian Peak Log10 Viral Load (At Rebound) Prior to Re-Starting ARTTime frame: Up to 112 weeks
  • EditedMedian Time to First Rebound to >=≥ 1000 Copies/mL During ART InterruptionTime frame: Up to 112 weeks
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Results posted
    6 sites added, 6 sites removed
    Show 6 added (3 United States, 2 Canada, 1 Italy)
    • Ahf Healthcare Center - Northpoint /ID# 256934 · Fort Lauderdale, United States
    • Metro Infectious Disease Consultants /ID# 256955 · Decatur, United States
    • The University of New Mexico /ID# 257533 · Albuquerque, United States
    • Duplicate_Toronto General Hospital /ID# 256994 · Toronto, Canada
    • McGill University Health Centre - Glen Site. /ID# 256992 · Montreal, Canada
    • Azienda Ospedaliera Universitaria Federico II - Naples /ID# 257412 · Naples, Italy
    Show 6 removed
    • AIDS Healthcare Foundation (AHF) - Healthcare Center - Northpoint /ID# 256934 · Fort Lauderdale, United States
    • Metro Infectious Disease Consultants, P.L.L.C /ID# 256955 · Decatur, United States
    • Unmhsc /Id# 257533 · Albuquerque, United States
    • Toronto General Hospital /ID# 256994 · Toronto, Canada
    • McGill University Health Centre - Glen Site /ID# 256992 · Montreal, Canada
    • Azienda Ospedaliera Universitaria Federico II /ID# 257412 · Naples, Italy
    Primary outcomes 2 edited
    What changed in the outcomes
    • EditedPercentage of Participants withWith Viral Control Without Antiretroviral Therapy (ART) RestartTime frame: Week 24
    • EditedNumber of Participants withWith Adverse Events (AEs)Time frame: Up to approximately Week 112
    Secondary outcomes 2 edited
    What changed in the outcomes
    • EditedMedian Peak Log10 Viral Load (At Rebound) Prior to Re-Starting ARTTime frame: Up to 112 weeks
    • EditedMedian Time to First Rebound to >=≥ 1000 Copies/mL During ART InterruptionTime frame: Up to 112 weeks
    + 3 other changes: identifiers, verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06032546
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Sep 13, 2023
Start date
Oct 12, 2023
Primary completion
Sep 22, 2025
Completion
Sep 22, 2025
Results posted
Nov 6, 2026
Last update
Nov 6, 2026

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Budigalimab · Trosunilimab

Start the discussion